Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Co-occurrence of EGFR sensitising and resistance mutations at diagnosis in NSCLC.

Kelly D, Burke L, O'Brien C, Kearns R, Rafee S, Power D, O'Reilly S, O'Mahony D, Bambury R.

Ir J Med Sci. 2018 Jul 20. doi: 10.1007/s11845-018-1868-0. [Epub ahead of print]

PMID:
30030673
2.

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Urol Oncol. 2018 Jul;36(7):345-346. doi: 10.1016/j.urolonc.2018.05.011. Epub 2018 May 30.

PMID:
29859727
3.

Cancer Care Costs and Clinical Trials.

Kelly D, Brady C, Sui J, Cronin E, O'Hare D, Waldron J, O'Mahony D, Power D, Bambury RM, O'Reilly S.

Ir Med J. 2017 Apr 10;110(4):557. No abstract available.

PMID:
28665096
4.

A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South.

Kelly D, Mc Sorley L, O'Shea E, Mc Carthy E, Bowe S, Brady C, Sui J, Dawod MA, O'Brien O, Graham D, McCarthy J, Burke L, Power D, O'Reilly S, Bambury RM, Mahony DO.

Ir J Med Sci. 2017 Nov;186(4):855-857. doi: 10.1007/s11845-017-1579-y. Epub 2017 Feb 9.

PMID:
28185061
5.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.

6.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R.

JAMA Oncol. 2016 Nov 1;2(11):1441-1449. doi: 10.1001/jamaoncol.2016.1828. Erratum in: JAMA Oncol. 2016 Nov 1;2(11):1511.

7.

Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

Bambury RM, Rathkopf DE.

Urol Oncol. 2016 Aug;34(8):348-55. doi: 10.1016/j.urolonc.2015.05.025. Epub 2015 Jul 7. Review.

PMID:
26162486
8.

Empathy and the wounded healer: a mixed-method study of patients and doctors views on empathy.

Brady C, Bambury RM, O'Reilly S.

Ir Med J. 2015 Apr;108(4):125-6.

PMID:
26016309
9.

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE.

BMC Cancer. 2015 Apr 9;15:242. doi: 10.1186/s12885-015-1192-2.

10.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE.

Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.

11.

Enzalutamide: Development from bench to bedside.

Bambury RM, Scher HI.

Urol Oncol. 2015 Jun;33(6):280-8. doi: 10.1016/j.urolonc.2014.12.017. Epub 2015 Mar 18. Review.

PMID:
25797385
12.

HER2 as a target in invasive urothelial carcinoma.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J.

Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.

13.

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 Oct;4(10):1140-53. doi: 10.1158/2159-8290.CD-14-0623. Epub 2014 Aug 5.

14.

Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.

Bambury RM, Morris PG.

Anticancer Drugs. 2014 Jul;25(6):611-3. doi: 10.1097/CAD.0000000000000104. No abstract available.

PMID:
24858445
15.

The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.

Bambury RM, Morris PG.

Expert Rev Anticancer Ther. 2014 Aug;14(8):955-64. doi: 10.1586/14737140.2014.916214. Epub 2014 May 12. Review.

PMID:
24814143
16.

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA.

Invest New Drugs. 2014 Feb;32(1):178-87. doi: 10.1007/s10637-013-0045-6. Epub 2013 Nov 16.

17.

Actionable mutations in muscle-invasive bladder cancer.

Bambury RM, Rosenberg JE.

Curr Opin Urol. 2013 Sep;23(5):472-8. doi: 10.1097/MOU.0b013e328363a3cd. Review.

PMID:
23907505
18.

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme.

Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, Drake C, O'Dea P, Bermingham N, Keohane C, Grossman SA, Moylan EJ, O'Reilly S.

J Neurooncol. 2013 Aug;114(1):149-54. doi: 10.1007/s11060-013-1164-9. Epub 2013 Jun 19.

PMID:
23780645
19.

Specific PPAR gamma agonists may have different effects on cancer incidence.

Bambury RM, Iyer G, Rosenberg JE.

Ann Oncol. 2013 Mar;24(3):854. doi: 10.1093/annonc/mdt003. No abstract available.

PMID:
23417919
20.

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.

Bambury RM, Rosenberg JE.

Front Pharmacol. 2013 Feb 6;4:3. doi: 10.3389/fphar.2013.00003. eCollection 2013.

21.

Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors.

Bambury RM, Battley JE, McCarthy A, Brady C, O'Reilly S, Kelly PJ, O'Brien F, Sweeney P, Fleming S, Mayer NJ, Power DG.

Clin Genitourin Cancer. 2013 Sep;11(3):357-61. doi: 10.1016/j.clgc.2012.12.006. Epub 2013 Jan 16. No abstract available.

PMID:
23332637
22.

Prostate cancer: germline prediction for a commonly variable malignancy.

Bambury RM, Gallagher DJ.

BJU Int. 2012 Dec;110(11 Pt C):E809-18. doi: 10.1111/j.1464-410X.2012.11450.x. Epub 2012 Sep 14. Review.

23.

Intratumor heterogeneity and branched evolution.

Bambury RM, Power DG, O'Reilly S.

N Engl J Med. 2012 May 31;366(22):2132; author reply 2133. doi: 10.1056/NEJMc1204069. No abstract available.

PMID:
22646642
24.

Primary cardiac lymphoma: diagnostic tools and treatment challenges.

Bambury R, Gallagher F, Dodd JD, Fennelly D.

Ir J Med Sci. 2011 Mar;180(1):271-3. doi: 10.1007/s11845-009-0446-x. Epub 2009 Nov 17.

PMID:
19921311
25.

Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.

Bambury R, McCaffrey JA.

Clin Colorectal Cancer. 2009 Oct;8(4):235. doi: 10.3816/CCC.2009.n.040. No abstract available.

PMID:
19822516
26.

Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metabolite.

Bambury RE, Feeley DT, Lawton GC, Weaver JM, Wemple J.

J Med Chem. 1984 Dec;27(12):1613-21.

PMID:
6389864
27.

Synthesis of 4-substituted aminoquinoline-3-carboxylates as potential antimicrobial agents.

Marecki PE, Bambury RE.

J Pharm Sci. 1984 Aug;73(8):1141-3.

PMID:
6491920
28.

beta-lactam antibiotics derived from nitrogen heterocyclic acetic acids. 2. Cephalosporin derivatives.

Bambury RE, Böhme EH, Brake NW, Edwards ML, Erickson RC, Fike WW, Hoffman PF, McCarty FJ, Paolini JP, Schnettler RA.

J Antibiot (Tokyo). 1981 Jan;34(1):40-6.

29.

Orally active cephalosporins and penicillins.

Böhme EH, Bambury RE, Baumann RJ, Erickson RC, Harrison BL, Hoffman PF, McCarty FJ, Schnettler RA, Vaal MJ, Wenstrup DL.

J Med Chem. 1980 Apr;23(4):405-12.

PMID:
7381838
30.

Nitrones. 7. alpha-Quinoxalinyl-N-substituted nitrone 1,4-dioxides.

Kim HK, Miller LF, Bambury RE, Ritter HW.

J Med Chem. 1977 Apr;20(4):557-60.

PMID:
557559
31.

Beta-lactam antibiotics with N-oxide side chains. 1. Quinoxaline N-oxides.

Edwards ML, Bambury RE, Ritter HW.

J Med Chem. 1976 Feb;19(2):330-3.

PMID:
814237
32.

3-Substituted 2-formylquinoxaline 1,4-dioxides.

Edwards ML, Bambury RE, Ritter HW.

J Med Chem. 1975 Jun;18(6):637-9.

PMID:
239234
33.

Nitrones. 6. -(5-Nitroimidazol-2-yl)-N-substituted nitrones.

Bambury RE, Lutz CM, Miller LF, Kim HK, Ritter HW.

J Med Chem. 1973 May;16(5):566-8. No abstract available.

PMID:
4198029
34.

1-H-imidazo(1,2-a)imidazoles.

Miller LF, Bambury RE.

J Med Chem. 1972 Apr;15(4):415-7. No abstract available.

PMID:
5019564
35.

2-amino-5-nitroimidazoles.

Miller LF, Bambury RE.

J Med Chem. 1971 Dec;14(12):1217-8. No abstract available.

PMID:
5165606
36.

Nitrones. 5. Vinylogs of alpha-(5-nitro-2-heteroaryl)-N-substituted nitrones.

Kim HK, Bambury RE.

J Med Chem. 1971 Apr;14(4):366-7. No abstract available.

PMID:
5553753
37.

Nitrones. 3. Alpha-(5-Nitro-2-furyl)-N-hydroxyalkylnitrones and their derivatives.

Kim HK, Bambury RE, Yaktin HK.

J Med Chem. 1971 Apr;14(4):301-4. No abstract available.

PMID:
5553741
38.

1-Substituted 2,5-dimethylpyrroles.

Miller LF, Bambury RE.

J Med Chem. 1970 Sep;13(5):1022-3. No abstract available.

PMID:
5458354
39.

Nitrones. II. alpha-(5-nitro-2-furyl)-n-cycloalkyl- and -N-alkylnitrones.

Kim HK, Yaktin HK, Bambury RE.

J Med Chem. 1970 Mar;13(2):238-41. No abstract available.

PMID:
5418495
40.

Nitrones. I. alpha-(5-Nitro-2-furyl)-N-arylnitrones.

Kim HK, Bambury RE.

J Med Chem. 1969 Jul;12(4):719-20. No abstract available.

PMID:
4978370

Supplemental Content

Loading ...
Support Center